Rimegepant

Last updated

Rimegepant
Rimegepant.svg
Clinical data
Trade names Nurtec ODT, Vydura
Other namesBHV-3000, BMS-927711
AHFS/Drugs.com Monograph
MedlinePlus a620031
License data
Pregnancy
category
Routes of
administration 		By mouth
Drug class Calcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
  • [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C28H28F2N6O3
Molar mass 534.568 g·mol−1
3D model (JSmol)
  • N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
  • InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
  • Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. [6] [8] It is taken by mouth to dissolve on or under the tongue. [6] It works by blocking CGRP receptors. [9]

Contents

In the United States, rimegepant was approved for treating acute migraine in February 2020, [10] and its approval was extended to preventing episodic migraine in June 2021. [6] It is produced and marketed by Pfizer. [11] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel. [12] [13] [14] It was approved for medical use in Canada in December 2023. [3]

Medical uses

Rimegepant is indicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults. [6] [8] [7]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. [9]

History

Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020. [10] [15] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches. [8]

Society and culture

On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine. [16] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC. [16] Rimegepant was approved for medical use in the European Union in April 2022. [7] [17]

Related Research Articles

<span class="mw-page-title-main">European Medicines Agency</span> Agency of the European Union

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

<span class="mw-page-title-main">Gemtuzumab ozogamicin</span> Pharmaceutical drug

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate that is used to treat acute myeloid leukemia.

Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

<span class="mw-page-title-main">Lasmiditan</span> Chemical compound

Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute treatment of migraine with or without aura in adults. It is not useful for prevention. It is taken by mouth.

<span class="mw-page-title-main">Ruxolitinib</span> Medication

Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease. Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi.

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.

<span class="mw-page-title-main">Galcanezumab</span> Monoclonal antibody

Galcanezumab, sold under the brand name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is also used for cluster headaches.

Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by injection under the skin.

<span class="mw-page-title-main">Ivosidenib</span> Anti-cancer medication

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.

<span class="mw-page-title-main">Ubrogepant</span> Medication for migraine headache acute treatment

Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine. Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist. It is the first drug in this class approved for the acute treatment of migraine.

<span class="mw-page-title-main">Abrocitinib</span> Chemical compound

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.

<span class="mw-page-title-main">Pemigatinib</span> Pharmaceutical drug

Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.

<span class="mw-page-title-main">Ripretinib</span> Chemical compound

Ripretinib, sold under the brand name Qinlock, is a medication for the treatment of adults with advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract. It is taken by mouth. Ripretinib inhibits the activity of the kinases KIT and PDGFRA, which helps keep cancer cells from growing.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. It was developed by BioMarin Pharmaceutical. Valoctocogene roxaparvovec is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in people with hemophilia A. It is an adeno-associated virus vector-based gene therapy. It is given by intravenous infusion.

<span class="mw-page-title-main">Maralixibat chloride</span> Chemical compound

Maralixibat chloride, sold under the brand name Livmarli, is a medication used to treat cholestatic pruritus in people with Alagille syndrome. Maralixibat chloride is an ileal bile acid transporter (IBAT) inhibitor.

<span class="mw-page-title-main">Avacopan</span> Chemical compound

Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.

Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL-36R) antagonist. It is given via injection into a vein.

References

  1. 1 2 "Nurtec ODT". Therapeutic Goods Administration (TGA). 8 August 2023. Retrieved 10 September 2023.
  2. ↑ "Nurtec ODT (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 22 August 2023. Retrieved 10 September 2023.
  3. 1 2 https://pdf.hres.ca/dpd_pm/00073578.PDF
  4. ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28]". Health Canada . 28 February 2024. Retrieved 2 March 2024.
  5. ↑ "Details for: Nurtec ODT". Health Canada . 1 December 2023. Retrieved 3 March 2024.
  6. 1 2 3 4 5 "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
  7. 1 2 3 "Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 16 October 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. 1 2 3 "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  9. 1 2 Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–1022. doi:10.1016/S1474-4422(15)00198-2. PMID   26376968. S2CID   26523013.
  10. 1 2 "Drug Approval Package: Nurtec ODT". U.S. Food and Drug Administration (FDA). 26 March 2020. Archived from the original on 27 December 2021. Retrieved 16 October 2022.
  11. ↑ "Pfizer Completes Acquisition of Biohaven Pharmaceuticals". Pfizer (Press release). 3 October 2022. Archived from the original on 5 October 2022. Retrieved 16 October 2022.
  12. ↑ "Biohaven Pharma's Nurtec ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  13. ↑ "Nurtec ODT: Treatment and Prevention of Migraine? And How to Get It". Migraine Again. 14 April 2021. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  14. ↑ "Biohaven's Nurtec ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals (Press release). Archived from the original on 11 March 2021. Retrieved 3 June 2021.
  15. ↑ "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020. Archived from the original on 26 July 2021. Retrieved 28 February 2020– via PR Newswire.
  16. 1 2 "Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  17. ↑ "Vydura Product information". Union Register of medicinal products. Retrieved 3 March 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.